查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602415

成人血红素血症检测市场：按群体、类型和最终用户划分 - 全球预测 2025-2030

Adult Hemoglobinopathy Testing Market by Group (Structural Hemoglobin Variants, Thalassemia Syndromes), Type (Hb Electrophoresis, HPLC Detection, Mass Spectrometry), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年成人血红素血症检测市值为47.2亿美元，预计2024年将达到51亿美元，复合年增长率为6.17%，到2030年将达到71.8亿美元。

成人血红蛋白血症检测与以成人血红蛋白异常产生为特征的遗传性疾病（例如镰状细胞病和β地中海贫血）的诊断评估有关。此测试的范围和定义包括基因筛检、电泳和其他先进的诊断技术来识别血红蛋白疾病。此测试对于促进早期诊断、评估严重程度和确定治疗策略是必要的。应用范围从产前筛检到基于人群的研究，有助于优化个人化护理并改善公共卫生结果。最终用户主要包括医院、诊断实验室和研究机构。由于意识的提高、基因检测方法的技术进步以及新兴市场的政府倡议，血红蛋白病患病率上升对市场成长产生了重大影响。研究表明，将人工智慧和机器学习整合到诊断过程中可以透过提高准确性和降低成本提供重要的商机，而生物技术公司和研究机构之间的合作可以进一步推动创新。然而，市场面临挑战，包括检测技术高成本、资源匮乏环境下的访问受限以及对熟练医疗保健专业人员的需求。此外，设备和操作的高成本也是小型测试设施采用的障碍。有开发具有成本效益的高通量筛检方法和携带式诊断的创新和研发机会。此外，CRISPR 和基因编辑技术的进步可能会提供治疗解决方案，并代表另一种研究和开发途径。市场的竞争性和协作性需要策略伙伴关係来进行业务扩展和研发投资。上市公司应专注于广泛的可及性和可负担性，同时与公共卫生机构合作克服监管障碍。成功的进入者和现有企业应致力于透过技术调整优先考虑差异化并解决农村和服务不足人口的未满足需求，从而有效占领市场。

主要市场统计
基准年[2023] 47.2亿美元
预测年份 [2024] 51亿美元
预测年份 [2030] 71.8亿美元
复合年增长率（%） 6.17%

市场动态：快速发展的成人血红蛋白血症检测市场的关键市场洞察

成人血红蛋白血症检测市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 地中海贫血和镰状细胞疾病 (SCD) 的全球盛行率
    • 疾病的早​​期诊断和治疗趋势
    • 需要持续的新生儿筛检计划和准确可靠的检测方法
  • 市场限制因素
    • 成人血红素血症检测相关的高成本
  • 市场机会
    • 成人血红素病检测方法的技术进步
    • 成人血红蛋白病的持续研究与开发
  • 市场挑战
    • 成人血红素血症检测设备的技术限制

波特五力：驾驭成人血红素血症检测市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对成人血红素血症检测市场的影响

外部宏观环境因素在塑造成人血红蛋白血症检测市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解成人血红素血症检测市场的竞争状况

成人血红素血症测试市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵成人血红素血症测试市场供应商的绩效评估

FPNV 定位矩阵是评估成人血红素血症测试市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划成人血红素血症检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，成人血红蛋白血症测试市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球地中海贫血和镰状细胞疾病 (SCD) 的盛行率
      • 疾病的早​​期诊断和治疗趋势
      • 新生儿筛检计划的继续以及对准确可靠的检测方法的需求
    • 抑制因素
      • 成人血红素病检测相关的高成本
    • 机会
      • 成人血红素病检测方法的技术进步
      • 成人血红蛋白病的持续研究与开发
    • 任务
      • 成人血红素病检测设备的技术限制
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章成人血红素血症检测市场（依群体）

  • 结构性血红素变异
  • 地中海贫血症候群

第七章成人血红素血症检测市场：依类型

  • 血红素电泳
  • 高效液相层析检测
  • 质谱分析

第八章成人血红素血症检测市场：依最终用途分类

  • 医院
  • 研究所
  • 医学研究机构

第九章 北美和南美成人血红素血症检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区成人血红素血症检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲成人血红素血症检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • ARKRAY, Inc.
  • Beckman Coulter, Inc. by Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Bluebird Bio, Inc.
  • Creative Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • HORIBA Group
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Sysmex Europe SE
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Trinity Biotech PLC
Product Code: MRR-C002B1C99763

The Adult Hemoglobinopathy Testing Market was valued at USD 4.72 billion in 2023, expected to reach USD 5.10 billion in 2024, and is projected to grow at a CAGR of 6.17%, to USD 7.18 billion by 2030.

Adult hemoglobinopathy testing pertains to the diagnostic evaluation of inherited disorders characterized by abnormal hemoglobin production, such as sickle cell disease and beta-thalassemia, in adults. The scope and definition of this testing encompass genetic screenings, electrophoresis, and other advanced diagnostic techniques to identify hemoglobinopathies. This testing is necessary for promoting early diagnosis, assessing severity, and guiding treatment decisions. Its applications range from prenatal screenings to population-based studies, serving in optimizing individualized care and improving public health outcomes. End-users primarily include hospitals, diagnostic laboratories, and research institutions. The market's growth is significantly influenced by a rising prevalence of hemoglobinopathies due to increased awareness, technological advancements in genetic testing methods, and government initiatives in emerging markets. Insights reveal that integrating AI and machine learning in diagnostic processes presents substantial opportunities by enhancing accuracy and reducing costs, while collaborations between biotech firms and research organizations can further spur innovation. However, the market faces challenges like high costs of testing technologies, limited access in low-resource settings, and a need for skilled healthcare professionals. High equipment and operational costs can also deter smaller laboratories from adoption. Innovation and research opportunities lie in developing cost-effective, high-throughput screening methods and portable diagnostics that could democratize accessibility. Furthermore, advancements in CRISPR and gene-editing technologies could potentially offer therapeutic solutions, highlighting another avenue for research and development. The market's nature is competitive yet collaborative, necessitating strategic partnerships for expansion and R&D investment. Companies should focus on broad accessibility and affordability, collaborating with public health entities to navigate regulatory hurdles. Successful entrants and established firms should prioritize differentiation through technological adaptation, addressing the unmet needs in rural and underserved populations for effective market capture.

KEY MARKET STATISTICS
Base Year [2023] USD 4.72 billion
Estimated Year [2024] USD 5.10 billion
Forecast Year [2030] USD 7.18 billion
CAGR (%) 6.17%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Adult Hemoglobinopathy Testing Market

The Adult Hemoglobinopathy Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of thalassemia and sickle cell disease (SCD) worldwide
    • Inclination toward early diagnosis and treatment of diseases
    • Ongoing newborn screening programs and need for accurate and reliable testing methodologies
  • Market Restraints
    • High cost associated with adult-hemoglobinopathy-testing
  • Market Opportunities
    • Technological advancements in adult-hemoglobinopathy-testing methods
    • Ongoing research and development on adult-hemoglobinopathy
  • Market Challenges
    • Technical limitations in devices used for adult-hemoglobinopathy-testing

Porter's Five Forces: A Strategic Tool for Navigating the Adult Hemoglobinopathy Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Adult Hemoglobinopathy Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Adult Hemoglobinopathy Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Adult Hemoglobinopathy Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Adult Hemoglobinopathy Testing Market

A detailed market share analysis in the Adult Hemoglobinopathy Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Adult Hemoglobinopathy Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Adult Hemoglobinopathy Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Adult Hemoglobinopathy Testing Market

A strategic analysis of the Adult Hemoglobinopathy Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adult Hemoglobinopathy Testing Market, highlighting leading vendors and their innovative profiles. These include ARKRAY, Inc., Beckman Coulter, Inc. by Danaher Corporation, Bio-Rad Laboratories, Inc., Bluebird Bio, Inc., Creative Diagnostics, F. Hoffmann-La Roche Ltd., HORIBA Group, Illumina, Inc., Laboratory Corporation of America Holdings, Merck KGaA, PerkinElmer, Inc., Quest Diagnostics Incorporated, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shimadzu Corporation, Siemens Healthineers AG, Sysmex Europe SE, Thermo Fisher Scientific Inc., Tosoh Corporation, and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Adult Hemoglobinopathy Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Group, market is studied across Structural Hemoglobin Variants and Thalassemia Syndromes.
  • Based on Type, market is studied across Hb Electrophoresis, HPLC Detection, and Mass Spectrometry.
  • Based on End-Use, market is studied across Hospital, Laboratories, and Medical & Research Institute.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of thalassemia and sickle cell disease (SCD) worldwide
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Ongoing newborn screening programs and need for accurate and reliable testing methodologies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with adult-hemoglobinopathy-testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in adult-hemoglobinopathy-testing methods
      • 5.1.3.2. Ongoing research and development on adult-hemoglobinopathy
    • 5.1.4. Challenges
      • 5.1.4.1. Technical limitations in devices used for adult-hemoglobinopathy-testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Adult Hemoglobinopathy Testing Market, by Group

  • 6.1. Introduction
  • 6.2. Structural Hemoglobin Variants
  • 6.3. Thalassemia Syndromes

7. Adult Hemoglobinopathy Testing Market, by Type

  • 7.1. Introduction
  • 7.2. Hb Electrophoresis
  • 7.3. HPLC Detection
  • 7.4. Mass Spectrometry

8. Adult Hemoglobinopathy Testing Market, by End-Use

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Laboratories
  • 8.4. Medical & Research Institute

9. Americas Adult Hemoglobinopathy Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Adult Hemoglobinopathy Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Adult Hemoglobinopathy Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ARKRAY, Inc.
  • 2. Beckman Coulter, Inc. by Danaher Corporation
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Bluebird Bio, Inc.
  • 5. Creative Diagnostics
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. HORIBA Group
  • 8. Illumina, Inc.
  • 9. Laboratory Corporation of America Holdings
  • 10. Merck KGaA
  • 11. PerkinElmer, Inc.
  • 12. Quest Diagnostics Incorporated
  • 13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 14. Shimadzu Corporation
  • 15. Siemens Healthineers AG
  • 16. Sysmex Europe SE
  • 17. Thermo Fisher Scientific Inc.
  • 18. Tosoh Corporation
  • 19. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADULT HEMOGLOBINOPATHY TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STRUCTURAL HEMOGLOBIN VARIANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA SYNDROMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HB ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HPLC DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MEDICAL & RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2023